FIELD: medicine; immunology; experimental medicine.
SUBSTANCE: invention can be used for the selective destruction of macrophages in a cell suspension or in the body. The method involves adding the drug either directly to the nutrient medium for culturing living cells, or introducing it intravenously into the mouse. A colloidal silver preparation, either protargol or collargol, is used as a selective toxic agent for macrophages. When conducting experiments under conditions of artificial cultivation of macrophages isolated from the mouse body, the concentration range is from 10 to 20 μg/ml, exposure is 4 hours with each agent separately. In experiments where the drug is administered directly into the mouse’s body intravenously, a dose of 1 mg/kg of animal weight and an exposure time of 24 hours with each agent separately are used.
EFFECT: use of the invention makes it possible to achieve selective destruction of mouse macrophages while reducing toxicity, minimizing the doses used, good solubility and ease of use.
1 cl, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
IMMUNOSTIMULATING AGENT | 1993 |
|
RU2098110C1 |
IMMUNODEPRESSANT | 1989 |
|
RU2045265C1 |
IMMUNOMODULATING AGENT | 1993 |
|
RU2108100C1 |
IMMUNOMODULATOR | 2019 |
|
RU2702114C1 |
IMMUNOMODULATORY DRUG | 2011 |
|
RU2470656C1 |
BIOLOGICALLY ACTIVE PREPARATION SHOWING IMMUNOMODULATING PROPERTIES | 1993 |
|
RU2048816C1 |
METHOD OF TREATING MALIGNANT TUMORS WITH A SUSPENSION OF NEUTROPHILS TREATED OUTSIDE THE BODY (EX VIVO) WITH GEL-FORMING PREPARATIONS OF Λ- OR K-CARRAGEENAN | 2022 |
|
RU2811809C2 |
IMMUNOMODULATORY DRUG | 2010 |
|
RU2421232C1 |
IMMUNOMODULATING AGENT | 2003 |
|
RU2224512C1 |
METHOD OF IMMUNOSUPPRESSION | 2008 |
|
RU2393481C1 |
Authors
Dates
2024-01-17—Published
2022-08-12—Filed